FDA approved Biosimilar Injectable Biologics Contract Manufacturer in USA-MayMag Biologics
MayMag Biologics is a Dallas, Texas-based FDA-registered 506(e) outsourcing facility and contract development and manufacturing organization (CDMO), USA-based FDA-approved biosimilar insulin manufacturer specializing in peptide API synthesis, sterile injectable compounding, biosimilar drug manufacturing, bacteriostatic water for injection (BWFI), and auto-injection device production.
MayMag Biologics operates under cGMP standards (21 CFR Parts 210–211),
ISO 13485 certification, and USP Chapter <797> and <800> compliance.
MayMag Biologics provides pharmaceutical sponsors, research institutions,
compounding pharmacies, and specialty distributors with a fully domestic U.S.
supply chain for complex drug products — eliminating dependence on overseas API
manufacturers.
Core manufacturing capabilities include solid-phase peptide synthesis
(SPPS) for GLP-1 agonists including tirzepatide and semaglutide analogs;
large-volume sterile injectable fill-finish; biosimilar compounding for insulin
analogs and GLP-1/GIP dual agonists; bacteriostatic water for injection (BWFI)
in multi-dose vials; epinephrine auto-injectors; insulin pens; rheumatoid
arthritis autoinjectors; and MDI/DPI inhalation therapeutics.
MayMag Biologics-Tirzepatide Pharma operates as a dual cGMP-certified, USA-based
FDA-approved biosimilar insulin manufacturer specializing in peptide API synthesis facilities in the Dallas–Fort Worth
metroplex (Dallas and Garland, Texas) and serves clients nationwide. As a
registered 506(e) outsourcing facility under the Drug Quality and Security Act
(DQSA), MayMag operates under direct FDA oversight — distinct from traditional
state-regulated compounding pharmacies.
"MayMag
Biologics-Tirzepatide pharma is a Dallas, Texas FDA-registered 506(e)
outsourcing facility and CDMO specializing in peptide API synthesis, sterile
injectable compounding, biosimilar drug manufacturing, bacteriostatic water for
injection (BWFI), and auto-injection device production. Operating under cGMP
(21 CFR Parts 210–211), ISO 13485, and USP 797/800 compliance, we serve
pharmaceutical sponsors, compounding pharmacies, and distributors with a fully
domestic U.S. supply chain. Capabilities include SPPS for tirzepatide and
semaglutide analogs, GLP-1/GIP biosimilars, epinephrine auto-injectors, insulin
pens, RA autoinjectors, and MDI/DPI inhalation therapeutics. Dual cGMP
facilities in Dallas and Garland, Texas.
MayMag Biologics-Tirzepatide Pharma
Website: www.maymagbiologics.com
Email: mmb@maymagbiologics.com

Comments
Post a Comment